AstraZeneca PLC
03 November 2004
ASTRAZENECA TO ADD RESULTS FROM ONGOING STUDIES IN RESUBMITTED SYMBICORT SINGLE
INHALER THERAPY FILE IN THE EU
AstraZeneca announced today that it has withdrawn its Symbicort Single Inhaler
Therapy file for the EU. As a result of discussions during the Mutual
Recognition Process, AstraZeneca expects a file to be submitted in the second
half of next year (2005), with additional data from recently completed (COSMOS)
and ongoing studies designed to provide further confirmation of this new
treatment concept.
Symbicort Single Inhaler Therapy is an innovative approach to the treatment of
asthma. AstraZeneca has already provided clear evidence that, when compared to
today's gold-standard treatments, it shows clinically significant benefits for
patients. Symbicort Single Inhaler Therapy yields a reduction of asthma
exacerbations, a reduced need for other treatments, a reduction in the number of
hospitalisations/emergency room visits and a decrease in overall corticosteroid
load. AstraZeneca firmly believes that this new treatment concept has a very
important role to play in the future management of asthma.
AstraZeneca is a major international healthcare business engaged in the
research, development, manufacture and marketing of prescription pharmaceuticals
and the supply of healthcare services. It is one of the world's leading
pharmaceutical companies with healthcare sales of over $18.8 billion and leading
positions in sales of gastrointestinal, oncology, cardiovascular, neuroscience
and respiratory products. AstraZeneca is listed in the Dow Jones Sustainability
Index (Global) as well as the FTSE4Good Index.
3 November 2004
Media Enquiries:
Edel McCaffrey, Tel: +44 (0) 207 304 5034
Steve Brown, Tel: +44 (0) 207 304 5033
Investor Relations:
Mina Blair, Tel: +44 (0) 207 304 5084
Jonathan Hunt, Tel: +44 (0) 207 304 5087
-Ends-
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.